Tags: Drug.

BMS-345541 marketed by Merck KGaA is an anti-inflammatory cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.

BMS-345541.png
IUPAC name
4-(2′-Aminoethyl)amino-18-dimethylimidazo[12-a]quinoxaline
PubChem
9813758

Loading...

This page contains content from the copyrighted Wikipedia article "BMS-345541"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.